{
    "clinical_study": {
        "@rank": "67096", 
        "arm_group": [
            {
                "arm_group_label": "NVN1000 4% Gel", 
                "arm_group_type": "Experimental", 
                "description": "NVN1000 4% Gel twice daily to the face for 2 weeks"
            }, 
            {
                "arm_group_label": "Vehicle Gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle Gel twice daily to the face for 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 2 week Phase 1 study of SB204 (NVN1000 Gel) in healthy adult volunteers with\n      elevated Propionibacterium acnes (P. acnes) counts.  Subjects will apply NVN1000 4% Gel or\n      Vehicle Gel twice daily to their face.  Assessments will include cutaneous tolerability,\n      safety, and P. acnes counts."
        }, 
        "brief_title": "A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "detailed_description": {
            "textblock": "In this single-center, vehicle gel-controlled, evaluator and subject blinded study,\n      approximately 30 otherwise healthy adult subjects with elevated P. acnes counts will be\n      randomized 2:1 to NVN1000 4% Gel or Vehicle Gel.  The subjects will apply the test material\n      twice daily to their face after washing.  Subjects will be seen daily at the skin study\n      center during the week and will apply their evening and weekend dose at home.  Cutaneous\n      tolerability will be assessed by the Investigator at Baseline, Week 1, and Week 2.  Safety\n      assessments include collection of adverse events, laboratory results, and clinically\n      significant changes in physical examination.  P. acnes counts will be obtained at Baseline,\n      Week 1 and Week 2."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult male or female volunteers\n\n          -  If a woman of child-bearing potential, agrees to use effective method of birth\n             control during the study and for 30 days after the final study visit\n\n          -  Agree to refrain from use of antimicrobial topical products during study\n\n        Exclusion Criteria:\n\n          -  Any skin disorders of acute or chronic nature including psoriasis, eczema, etc\n\n          -  Female subjects who are pregnant, nursing, or planning to become pregnant\n\n          -  Subjects who have used topical or systemic antibiotics, estrogens, drugs associated\n             with methemoglobinemia, nitrate donors\n\n          -  Subjects with baseline methemoglobin > 2%\n\n          -  Subjects with clinically significant anemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844739", 
            "org_study_id": "NI-AC006"
        }, 
        "intervention": [
            {
                "arm_group_label": "NVN1000 4% Gel", 
                "intervention_name": "NVN1000 4% Gel", 
                "intervention_type": "Drug", 
                "other_name": "SB204"
            }, 
            {
                "arm_group_label": "Vehicle Gel", 
                "intervention_name": "Vehicle Gel", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Propionibacterium acnes", 
            "acne"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Broomall", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19008"
                }, 
                "name": "KGL"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Multiple-dose, Evaluator-blind, Randomized, Parallel Group Study Evaluating the Safety and Cutaneous Tolerability of SB204 (NVN1000 Gel) in Healthy Volunteers", 
        "other_outcome": {
            "description": "P. acnes counts will be obtained by culture at Baseline, Week 1 and Week 2/end of treatment.  The change in P. acnes counts over time will be analyzed.", 
            "measure": "Change in P. acnes counts", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "overall_official": {
            "affiliation": "Novan, Inc.", 
            "last_name": "Joyce Rico, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Cutaneous tolerability assessments (erythema, scaling, dryness, pruritus, burning/stinging) will be summarized with frequency counts and percentages at each score category for Week 1 and Week 2.", 
            "measure": "Tolerability based on the cutaneous tolerability scores", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844739"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events will be summarized by treatment group.  Clinically significant changes in physical examination, including vital signs, over the treatment period will be reported as adverse events.  Changes in laboratory results will be analyzed.", 
            "measure": "Safety which includes reported adverse events, clinically significant changes in physical exam, and labs", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "source": "Novan, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novan, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}